Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis.
- Author(s): Gebremariam, Teclegiorgis
- Alkhazraji, Sondus
- Gu, Yiyou
- Singh, Shakti
- Alqarihi, Abdullah
- Shaw, Karen Joy
- Ibrahim, Ashraf S
- et al.
Published Web Locationhttps://doi.org/10.1128/aac.01966-19
Galactomannan (GM) detection in biological samples has been shown to predict therapeutic response by azoles and polyenes. In a murine invasive pulmonary aspergillosis model, fosmanogepix or posaconazole treatment resulted in an ∼6- to 7-log reduction in conidial equivalents (CE)/g lung tissue after 96 h versus placebo. Changes in GM levels in BAL fluid and serum mirrored reductions in lung CE, with significant decreases seen after 96 h or 72 h for fosmanogepix or posaconazole, respectively (P < 0.02).